Literature DB >> 26200282

Crizotinib Improves Osteoarthritis Symptoms in a ROS1-Fusion Advanced Non-Small Cell Lung Cancer Patient.

Jordi Remon1, Anas Gazzah, Benjamin Besse, Jean-Charles Soria.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26200282     DOI： 10.1097/JTO.0000000000000561

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  3 in total

Review 1.  Targeting VEGF and Its Receptors for the Treatment of Osteoarthritis and Associated Pain.

Authors:  John L Hamilton; Masashi Nagao; Brett R Levine; Di Chen; Bjorn R Olsen; Hee-Jeong Im
Journal:  J Bone Miner Res       Date:  2016-04-08       Impact factor: 6.741

2.  Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement.

Authors:  Limin Zhang; Tao Jiang; Chao Zhao; Wei Li; Xuefei Li; Sha Zhao; Xiaozhen Liu; Yijun Jia; Hui Yang; Shengxiang Ren; Caicun Zhou
Journal:  Oncotarget       Date:  2016-11-15

3.  The amelioration of cartilage degeneration by photo-crosslinked GelHA hydrogel and crizotinib encapsulated chitosan microspheres.

Authors:  Pengfei Chen; Sheng Mei; Chen Xia; Ren Zhu; Yichuan Pang; Jiying Wang; Jianfeng Zhang; Fangchun Shao; Shunwu Fan
Journal:  Oncotarget       Date:  2017-05-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.